Govt looking at mix-and-match of vaccine doses on trial basis: V K Paul

We are engaged with Pfizer as they have indicated the availability of a certain volume of vaccines in the coming months, possibly in July, says NITI member

V K Paul
Dr V K Paul, Member (Health), NITI Aayog. Credits: ANI
BS Web Team New Delhi
2 min read Last Updated : May 27 2021 | 5:24 PM IST
The government is looking to mix-and-match vaccine doses on a trial basis and there is no concern if just in case people are getting different doses, the government's top advisor said on Thursday.

"As per the protocol, stick to the same dose of vaccine as the first one. If in case people are getting different doses there is no cause for concern, it's safe. We are thinking to mix and match (vaccine doses) on a trial basis," said Dr V K Paul, a member (Health) of Niti Aayog.

V K Paul, while addressing the media on coronavirus situation in the country, said that the government is engaged with Pfizer as they have indicated the availability of a certain volume of vaccines in the coming months, possibly in July. 

"They have requested indemnity against liability to all the nations. We are examining this request. There is no decision as of now," he said.

Expressing optimism that the current wave is on the decline, V K Paul said: "It is reassuring that we are on the downswing of the second wave, and it will be sustained if restrictions open up systematically as the time comes.

India has recorded 211,298 fresh coronavirus in the last 24 hours. Deaths from the disease rose by 3,847. The country's total cases now stand at 27,369,093, while total fatalities are at 315,235, according to MoHFW.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story